Partner Content Partner Content Why switch to automated CRF annotations? Why it's best to automate CRF annotations
Oncology Following science to fruition, putting patients first: An AS... At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face